ABBV AbbVie Inc

Price (delayed)

$152.34

Market cap

$269.2B

P/E Ratio

21.79

Dividend/share

$5.42

EPS

$6.99

Enterprise value

$336.58B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The EPS has soared by 151% YoY and by 8% from the previous quarter
The company's net income has surged by 142% YoY and by 8% QoQ
The quick ratio has contracted by 8% YoY

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$269.2B
Enterprise value
$336.58B
Valuations
Price to earnings (P/E)
21.79
Price to book (P/B)
16.55
Price to sales (P/S)
4.76
EV/EBIT
20.59
EV/EBITDA
13.62
EV/Sales
5.93
Earnings
Revenue
$56.73B
EBIT
$16.34B
EBITDA
$24.7B
Free cash flow
$22.05B
Per share
EPS
$6.99
Free cash flow per share
$12.45
Book value per share
$9.21
Revenue per share
$32.03
TBVPS
$20.85
Balance sheet
Total assets
$143.21B
Total liabilities
$126.9B
Debt
$73.47B
Equity
$16.28B
Working capital
-$6.01B
Liquidity
Debt to equity
4.51
Current ratio
0.82
Quick ratio
0.56
Net debt/EBITDA
2.73
Margins
EBITDA margin
43.5%
Gross margin
69.5%
Net margin
22%
Operating margin
32.7%
Efficiency
Return on assets
8.5%
Return on equity
86.3%
Return on invested capital
21.6%
Return on capital employed
14.8%
Return on sales
28.8%
Dividend
Dividend yield
3.56%
DPS
$5.42
Payout ratio
77.5%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
1.93%
1 week
10.17%
1 month
2.17%
1 year
32.77%
YTD
12.51%
QTD
-6.03%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$56.73B
Gross profit
$39.44B
Operating income
$18.54B
Net income
$12.48B
Gross margin
69.5%
Net margin
22%
The company's net income has surged by 142% YoY and by 8% QoQ
The net margin has surged by 114% year-on-year and by 7% since the previous quarter
The operating income has soared by 56% YoY and by 3.4% from the previous quarter
The operating margin rose by 39% year-on-year and by 2.5% since the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
21.79
P/B
16.55
P/S
4.76
EV/EBIT
20.59
EV/EBITDA
13.62
EV/Sales
5.93
The EPS has soared by 151% YoY and by 8% from the previous quarter
ABBV's P/E is 14% below its last 4 quarters average of 25.2 and 11% below its 5-year quarterly average of 24.5
AbbVie's equity has increased by 19% YoY and by 6% from the previous quarter
ABBV's price to book (P/B) is 4.7% higher than its last 4 quarters average of 15.8
ABBV's P/S is 16% above its last 4 quarters average of 4.1 and 13% above its 5-year quarterly average of 4.2
ABBV's revenue is up by 13% year-on-year

Efficiency

How efficient is AbbVie business performance
AbbVie's ROIC has soared by 177% YoY and by 9% from the previous quarter
AbbVie's return on assets has surged by 150% YoY and by 9% QoQ
The ROE has soared by 137% YoY and by 3.2% from the previous quarter
The ROS has soared by 118% YoY and by 5% from the previous quarter

Dividends

What is ABBV's dividend history
DPS
$5.42
Dividend yield
3.56%
Payout ratio
77.5%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 13% higher than its total liabilities
The quick ratio has contracted by 8% YoY
The total liabilities has declined by 7% year-on-year and by 3.2% since the previous quarter
The company's debt to equity fell by 28% YoY and by 9% QoQ
AbbVie's equity has increased by 19% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.